原发性硬化性胆管炎合并炎症性肠病的研究进展  

Research progress on primary sclerosing cholangitis complicated with inflammatory bowel disease

作　　者：吴朴仙 林婧 任鹏程 王红霞 王祥[2] Wu Puxian;Lin Jing;Ren Pengcheng;Wang Hongxia;Wang Xiang(The Second Clinical Medical School,Lanzhou University,Lanzhou 730000,China;Department of Gastroenterology,the Second Hospital,Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第二临床医学院,兰州730000 [2]兰州大学第二医院消化科,兰州730000

出　　处：《中国医药》2025年第1期148-152,共5页China Medicine

基　　金：甘肃省自然科学基金(21JR7RA409);甘肃省重点研发计划(21YF5FA124)。

摘　　要：原发性硬化性胆管炎(PSC)是一种胆道的慢性胆汁淤积性疾病,在病程中常合并炎症性肠病(IBD)。PSC与IBD共存时表现出不同于独立疾病的临床表型、疾病转归和肿瘤风险,影响疾病的治疗和管理。本文就PSC合并IBD的发病机制、病程间的相互影响以及相关恶性肿瘤的风险及监测进行综述,以期增强临床医师对于疾病的认识,并为PSC合并IBD的临床研究和诊疗提供新的思路。Primary sclerosing cholangitis(PSC)is a chronic cholestatic disease of the biliary tract,which is often accompanied by inflammatory bowel disease(IBD).PSC coexisting with IBD shows different clinical phenotypes,disease outcome and tumor risk from independent diseases,which affects the treatment and management of the disease.This article reviews the pathogenesis of PSC complicated with IBD,the interaction between the course of disease,and the risk and monitoring of related malignant tumors,in order to enhance clinicians′understanding of the disease and provide new ideas for the clinical research and diagnosis and treatment of PSC complicated with IBD.

关 键 词：原发性硬化性胆管炎 炎症性肠病 发病机制 临床特征 肿瘤 

分 类 号：R657.4[医药卫生—外科学]